Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
暂无分享,去创建一个
R. Gascoyne | K. Savage | J. Connors | R D Gascoyne | J M Connors | M. Chhanabhai | K J Savage | M Chhanabhai
[1] S. Pileri,et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] T. Greiner,et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. , 1999, Blood.
[3] D. Wright,et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Freund,et al. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation , 2002, Annals of Hematology.
[5] Keunchil Park,et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. , 2002, European journal of cancer.
[6] M. Kadin,et al. Systemic and primary cutaneous anaplastic large cell lymphomas. , 2003, Seminars in hematology.
[7] P. Gaulard,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.
[8] E. Jaffe,et al. Nasal Lymphomas in Peru: High Incidence of T-Cell Immunophenotype and Epstein-Barr Virus Infection , 1993, The American journal of surgical pathology.
[9] K. Yeh,et al. Combination of 13-cis Retinoic Acid and Interferon-α in the Treatment of Recurrent or Refractory Peripheral T-cell Lymphoma , 2002, Leukemia & lymphoma.
[10] Elaine S. Jaffe,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[11] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[12] R. Warnke,et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. Bergmann,et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. , 1996, Leukemia & lymphoma.
[14] K. Karube,et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. , 2004, Blood.
[15] F. Berger,et al. Original article: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen , 1990 .
[16] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[17] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[18] T. Habermann,et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Gascoyne. Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Hematology/oncology clinics of North America.
[20] P. Gaulard,et al. Clinical and biological analysis of peripheral T-cell lymphomas: a single institution study. , 1992, Leukemia & lymphoma.
[21] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[22] J. Delabie,et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas , 2001, Bone Marrow Transplantation.
[23] J. Diebold,et al. UPDATED KIEL CLASSIFICATION FOR LYMPHOMAS , 1988, The Lancet.
[24] J. Armitage. The changing classification of non‐Hodgkin's lymphomas , 1997, CA: a cancer journal for clinicians.
[25] C. Meijer,et al. ALK‐negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects–a review , 2003, The Journal of pathology.
[26] James Olen Armitage,et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.
[27] F. Berger,et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] B. Nathwani,et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Juan F. García,et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. , 2003, Blood.
[30] M. Munsell,et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] E. Iannitto,et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.
[32] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[33] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[35] R. Gascoyne,et al. Clinical utility of heteroduplex analysis of TCR gamma gene rearrangements in the diagnosis of T-cell lymphoproliferative disorders. , 1997, American journal of clinical pathology.
[36] T. Molina,et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. , 1999, Leukemia & lymphoma.
[37] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[38] J. Chan,et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. , 2002, International journal of radiation oncology, biology, physics.
[39] P. Meyers. High-dose therapy with autologous stem cell rescue for pediatric sarcomas , 2004, Current opinion in oncology.
[40] M. Valentine,et al. Sequence Correction , 1995, Science.
[41] A. Melnyk,et al. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[42] R. Gascoyne,et al. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. , 1995, American journal of clinical pathology.
[43] Y. C. Chen,et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately? , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] D. Hossfeld. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .
[45] E. Jaffe,et al. Nasal Lymphomas in Peru , 1993 .
[46] K. Lennert,et al. UPDATED KIEL CLASSIFICATION FOR LYMPHOMAS , 1988, The Lancet.
[47] W. Au,et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. , 2004, Blood.
[48] W. Wilson,et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.
[49] R. Fanin,et al. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT) , 1999, Bone Marrow Transplantation.
[50] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[51] A. López-Guillermo,et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[53] P. Gaulard,et al. Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.